Use este identificador para citar ou linkar para este item: https://repositorio.ufba.br/handle/ri/17510
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorOliveira, Márcio Galvão-
dc.contributor.authorPassos, Luiz Carlos-
dc.contributor.authorSantos Júnior, Edval Gomes dos-
dc.contributor.authorBarbosa, Andréa Cristina Costa-
dc.contributor.authorSantos, Djanilson Barbosa-
dc.creatorOliveira, Márcio Galvão-
dc.creatorPassos, Luiz Carlos-
dc.creatorSantos Júnior, Edval Gomes dos-
dc.creatorBarbosa, Andréa Cristina Costa-
dc.creatorSantos, Djanilson Barbosa-
dc.date.accessioned2015-04-30T13:19:07Z-
dc.date.available2015-04-30T13:19:07Z-
dc.date.issued2013-
dc.identifier.issn1984-8250-
dc.identifier.urihttp://repositorio.ufba.br/ri/handle/ri/17510-
dc.descriptionp.831-836pt_BR
dc.description.abstractThe aim of this study was to use indicators to evaluate physician adherence to prescription guidelines for heart failure treatment in a university hospital. This was a prospective cohort study conducted in a university hospital. The information collected at the time of patient admission, including therapeutic indication, absolute contra indications and intolerance, was utilised for the formulation of a guideline adherence indicator (GAI). This indicator was calculated as follows: (the number of patients who used the medication/the number of eligible patients) x 100. The percentage of eligible patients was calculated using the following formula: (the number of eligible patients/the total number patients) x 100. The GAI was applied to a population of 53 patients. Inhibitors of angiotensin-converting enzyme/angiotensin receptor blocker (ACE-I/ARB) combination therapy were used in the greatest percentage of eligible patients (92.4%) and demonstrated the largest GAI value (73.5%). The percentages of patients who were eligible for beta-blockers, spironolactone and digitalis treatments were 81.1%, 52.8% and 60.4%, respectively. The GAI values for the use of beta-blockers, spironolactone and digitalis were 60.4%, 57.1% and 56.2%, respectively. For the studied patient population, the GAI was consistent with the proportion of patients who were eligible to receive digitalis and spironolactone.pt_BR
dc.language.isoenpt_BR
dc.rightsAcesso Abertopt_BR
dc.sourcehttp://dx.doi.org/10.1590/S1984-82502013000400023pt_BR
dc.subjectHeart failure/treatmentpt_BR
dc.subjectHealth carept_BR
dc.subjectClinical medicine/practice guidelinespt_BR
dc.subjectMedicines/usept_BR
dc.subjectMedicines/prescriptionspt_BR
dc.titleUse of an indicator to evaluate physician adherence to prescription guidelines for the treatment of heart failurept_BR
dc.title.alternativeBrazilian Journal of Pharmaceutical Sciencespt_BR
dc.typeArtigo de Periódicopt_BR
dc.identifier.numberv. 49, n. 4pt_BR
Aparece nas coleções:Artigo Publicado em Periódico (ICS)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Márcio Galvão Oliveira.pdf248,88 kBAdobe PDFVisualizar/Abrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.